<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725933</url>
  </required_header>
  <id_info>
    <org_study_id>121ST101</org_study_id>
    <nct_id>NCT00725933</nct_id>
  </id_info>
  <brief_title>Administration of BIIB028 to Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 Administered to Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Tolerability of BIIB028&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of BIIB028</measure>
    <time_frame>As specified in Protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK and PD of BIIB028</measure>
    <time_frame>As specified in protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>As specified in protocol</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB028</intervention_name>
    <description>IV infusion administered twice weekly until disease progression or unacceptable toxicity</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information (PHI) in&#xD;
             accordance with national and local subject privacy regulations.&#xD;
&#xD;
          -  Age greater than or equal to 18 years at the time of informed consent.&#xD;
&#xD;
          -  Subjects with histological or cytological confirmed solid tumors who have failed&#xD;
             standard therapies or for which no standard therapy is available.&#xD;
&#xD;
          -  Anticipated survival of at least 3 months in the opinion of the Investigator.&#xD;
&#xD;
          -  ECOG performance status of less than or equal to 2.&#xD;
&#xD;
          -  Lab values consistent with adequate renal hepatic and bone marrow function.&#xD;
&#xD;
          -  Must utilize effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or nursing women&#xD;
&#xD;
          -  Prior treatment with Hsp90 inhibitors at any time.&#xD;
&#xD;
          -  Prior antitumor therapies including prior experimental agents, approved antitumor&#xD;
             small molecules and biologics, or radiotherapy with in 28 days or &lt;3 half lives&#xD;
             (whichever is longer). In addition,prior to enrollment, all asociated toxicities must&#xD;
             have been resolved to eligibility levels.&#xD;
&#xD;
          -  Concurrent severe or uncontrolled other medical disease (i.e, diabetes, hypertension,&#xD;
             coronary artery disease, congestive heart failure), which in the opinion of the&#xD;
             Investigator and/ or the Sponsor could compromise assessment of safety.&#xD;
&#xD;
          -  Use of anticoagulants, except low dose warfarin.&#xD;
&#xD;
          -  History of seizure, previous significant head trauma (e.g., associated with loss of&#xD;
             consciousness for more than 5 minutes), abrupt discontinuation of benzodiazepines, or&#xD;
             use of potentially epileptogenic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. doi: 10.1158/1078-0432.CCR-13-0477. Epub 2013 Jul 19.</citation>
    <PMID>23873691</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

